FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease
FUNDAMANT:一项为期 72 周的 AADvac1 介入性 1 期随访研究,AADvac1 是一种针对阿尔茨海默病 tau 蛋白病理的主动免疫疗法
期刊:Alzheimers Research & Therapy
影响因子:7.900
doi:10.1186/s13195-018-0436-1
Petr Novak, Reinhold Schmidt, Eva Kontsekova, Branislav Kovacech, Tomas Smolek, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek, Roman Sivak, Norbert Zilka, Bengt Winblad